抗弓形虫药物研究进展

Progress on Anti-Toxoplasma gondii Drugs

刚地弓形虫(Toxoplasma gondii)是一种呈世界范围分布的人兽共患寄生原虫,给人类生活和畜牧业生产带来极大的危害,然而至今仍没有理想的治疗弓形虫病的药物。近年来,研究人员主要从干扰弓形虫的叶酸代谢、检测抗其他病原微生物和寄生虫药物的抗弓形虫活性,以及针对弓形虫独特的生理结构和生化反应路径进行药物设计,开展抗弓形虫药物的研究,取得了许多重要的成果。随着人们对弓形虫研究的不断深入,对其分子生物学特性会有更加全面的了解,将给新的药物靶标的发现和特效药物的研发提供重要的理论依据。

Toxoplasma gondii can infect humans and animals worldwide,and cause serious results in immunosuppression people and pregnant women. However, there is no effect drugs against the parasite. In recent years, many achievements have been made in development of drugs against T. gondii, such as, interfereing with its folic acid metabolism, anti-T. gondii activities of the drugs used in other pathogenic microorganism and parasites, as well as designing drugs directly at the unique physiological structure and biochemical reaction pathways of T. gondii. Recently the molecular biological characteristics of this parasite have been understood more comprehensively and that will provides an important theoretical basis for the discovery of new drug targets and the development of specific remedy.